Sensorion to Present Promising SENS-401 Results at Upcoming Cochlear Implants Conference

Sensorion, a forward-thinking clinical-stage biotechnology company, is at the forefront of developing innovative therapies aimed at restoring, treating, and preventing hearing loss disorders. The company recently revealed that encouraging new data and analysis outcomes from its SENS-401 Phase 2a clinical study, conducted following cochlear implantation, will be showcased at the 17th International Conference on Cochlear Implants and Other Implantable Technologies (CI2024). This prestigious event is scheduled to take place from July 10-13, 2024, in Vancouver, Canada.

Professor Stephen O'Leary, M.D., Ph.D., who serves as the principal investigator for the study, will present the findings on July 13, 2024, at 9.40am (PDT) at the Vancouver Convention Centre. This research, conducted in partnership with Cochlear Limited, the global leader in implantable hearing devices, focuses on the potential of SENS-401 in preventing residual hearing loss post-cochlear implantation.

The presentation, titled "Early Preservation of Residual Hearing Six Weeks Post Cochlear™ Nucleus® CI622 Implantation and Detection of SENS-401 in Perilymph: Findings from a Phase IIa Clinical Trial Investigating Repeated Oral Administration of SENS-401 in Implant Patients," will highlight the pivotal insights gathered from this study. The venue for the presentation is the Vancouver Convention Centre, located at 1055 Canada Place, Vancouver, British Columbia.

Sensorion and Cochlear began their collaborative research on SENS-401 in 2017. Under their agreement, Cochlear has the option to negotiate a global license to distribute SENS-401 for specific applications related to implantable devices, once the complete data from the study is available.

SENS-401, also known as Arazasetron, is Sensorion’s leading clinical-stage drug candidate. It is an orally administered small molecule designed to protect and preserve inner ear tissue from damage that causes progressive or sequelae hearing impairment. Sensorion is currently advancing SENS-401 through a Phase 2a clinical trial aimed at preventing residual hearing loss in patients set for cochlear implantation. Additionally, SENS-401 is undergoing a Phase 2 clinical trial to prevent Cisplatin-Induced Ototoxicity. The drug has received Orphan Drug Designation from the European Medicines Agency (EMA) for treating sudden sensorineural hearing loss and from the U.S. Food and Drug Administration (FDA) for preventing platinum-induced ototoxicity in pediatric patients.

Sensorion is a clinical-stage biotech company dedicated to developing groundbreaking therapies for hearing loss disorders, which remain a significant unmet medical need worldwide. The company has built a unique research and development technology platform to deepen its understanding of the pathophysiology and etiology of inner ear diseases, enabling the selection of optimal targets and mechanisms for developing drug candidates.

The company is also engaged in gene therapy programs, which aim to correct hereditary monogenic forms of deafness. These programs are part of Sensorion's extensive strategic collaboration with the Institut Pasteur, focusing on the genetics of hearing. Sensorion's portfolio includes two gene therapy projects: SENS-501 (OTOF-GT), currently in a Phase 1/2 clinical trial targeting deafness caused by otoferlin gene mutations, and GJB2-GT, which addresses hearing loss related to GJB2 gene mutations in both adults and children. Additionally, the company is working on identifying biomarkers to enhance the diagnosis of these challenging conditions.

Sensorion's small molecule programs in clinical stages are designed for the treatment and prevention of hearing loss disorders. The portfolio includes SENS-401, which is in a Phase 2 proof of concept clinical study for Cisplatin-Induced Ototoxicity and a study for patients scheduled for cochlear implantation, conducted in collaboration with Cochlear Limited. Additionally, a Phase 2 study of SENS-401 concluded in January 2022 for Sudden Sensorineural Hearing Loss (SSNHL).